Loading...
Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
PURPOSE: Ovarian cancer is the most lethal gynaecological malignancy. Despite the introduction of bevacizumab, standard chemotherapy has remained largely unchanged and the vast majority of patients will relapse within the first two years of diagnosis. However, results from recent clinical trials dem...
Na minha lista:
| Udgivet i: | Arch Gynecol Obstet |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer Berlin Heidelberg
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7524817/ https://ncbi.nlm.nih.gov/pubmed/32833070 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00404-020-05677-1 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|